胰高血糖素樣肽-1是經(jīng)胰高血糖素原基因編碼、腸道L細(xì)胞分泌的多肽類物質(zhì)，在營(yíng)養(yǎng)物質(zhì)、細(xì)胞因子、神經(jīng)信號(hào)等刺激下通過(guò)促進(jìn)胰島素的分泌而發(fā)揮降糖作用。近年來(lái)，胰高血糖素樣肽-1受體激動(dòng)劑在2型糖尿病治療方面已獲肯定，與傳統(tǒng)降糖藥物相比，其除可以穩(wěn)定降糖外，還具有減重、降壓、調(diào)脂、心血管和腎臟保護(hù)等益處。主要對(duì)GLP-1受體激動(dòng)劑藥理作用的研究進(jìn)展進(jìn)行綜述。

Glucagon-like peptide-1 is a peptide encoded by proglucagon gen and secreted by intestinal tract L cell, and can reduce blood glucose through secreting enough insulin when stimulated by nutriment, cytokines, and neural signal. Recently, glucagon-like peptide-1 receptor agonists are widely applied in the treatment of type 2 diabetes mellitus. It also has benefits in weight loss, blood pressure reduction and lipid metabolism mediation and heart, kidney protection in addition to steady glucose control when compared with traditional hypoglycemic agents. Research progress on pharmacological action of glucagon-like peptide-1 receptor agonists are reviewed in this paper.

R977

天津市科技計(jì)劃項(xiàng)目（18YFZCSY00290、19YFZCSY00630）